March 5 (Reuters) - ARS Pharmaceuticals Inc SPRY.O:
ARS PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF NEFFY® 1 MG (EPINEPHRINE NASAL SPRAY) FOR TYPE I ALLERGIC REACTIONS, INCLUDING ANAPHYLAXIS, IN PEDIATRIC PATIENTS WEIGHING 15 TO < 30 KILOGRAMS
ARS PHARMACEUTICALS INC - NEFFY 1 MG IS EXPECTED TO BE AVAILABLE IN U.S. BY END OF MAY 2025
ARS PHARMACEUTICALS: MOST COMMERCIALLY INSURED PATIENTS WILL PAY NO MORE THAN $25 FOR TWO SINGLE-USE NEFFY DEVICES THROUGH A CO-PAY SAVINGS PROGRAM
ARS PHARMACEUTICALS INC: IF PRODUCT ISN'T COVERED BY INSURANCE, CASH PRICE OF $199 FOR TWO DOSES IS AVAILABLE THROUGH BLINKRX